甲状腺乳头状微小癌中央区淋巴结转移的预测因素  

Predictors for central lymph node metastases in papillary thyroid microcarcinoma

作　　者：武元元[1] 王军(审校)[1] 刘勤江[1] WU Yuanyuan;WANG Jun;LIU Qinjiang

机构地区：[1]甘肃省肿瘤医院头颈外科甘肃省头颈肿瘤外科临床医学中心,兰州730050

出　　处：《临床耳鼻咽喉头颈外科杂志》2020年第10期955-957,共3页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：甘肃省卫生行业科研计划项目(No:GSWSKY2018-05);陇原青年创新创业人才项目〔甘组通字(2019)39号〕。

摘　　要：近年来,甲状腺乳头状微小癌(papillary thyroid microcarcinoma,PTMC)在全球呈现出“爆发式”增长趋势。2014年世界癌症报告指出甲状腺癌新发病例中超过50%为PTMC。手术是PTMC最主要的治疗方法,但是否应该常规行预防性中央区淋巴结清扫术(PCND)争议很大,不同指南的推荐意见也有差异〔1〕。2015版ATA指南不推荐对cN0的T1期甲状腺乳头状癌(包括PTMC)行PCND〔2〕,以减少对喉返神经和甲状旁腺的损伤。我国PTMC诊断及治疗专家共识则建议在有技术保障(熟练掌握喉返神经和甲状旁腺显露及保留技巧)的条件下对cN0期PTMC患者行PCND〔3〕。产生争议的根本原因是术前缺乏对中央区淋巴结转移的准确预测,本文就PTMC颈部中央区淋巴结转移的预测因素作一综述。In recent years,with the wide application of ultrasound in health examination,the incidence of papillary thyroid microcarcinoma(PTMC)is increasing rapidly.There is more controversy about whether prophylactic central lymph node dissection(PCND)should be performed in PTMC patients with clinical lymph node negative(cN0).Some clinical and pathological factors were associated with central lymph node metastasis in patients with PTMC.This paper review the risk factors for predicting central lymph node metastasis so as to screen high-risk PTMC patients who need to receive PCND,and guide clinicians to choose reasonable individualized surgery.

关 键 词：甲状腺乳头状微小癌 淋巴结转移 危险因素 

分 类 号：R736.1[医药卫生—肿瘤]